RxDoctor Payments Data

Cassandra Morgan

Psychiatric/Mental Health · Joplin, MONPI 1649908229

Payments from drug & device makers

$1,522in general payments, 2019–2025

Across 21 payments — averaging $72.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$394
  • Axsome Therapeutics, Inc.$248
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$217
  • AbbVie$126
  • Vanda Pharmaceuticals Inc.$123
  • E.r. Squibb & Sons, L.L.C.$121
  • plus $294 from 6 others

What the payments were for

  • Food & beverage$1,49598%
  • Education$272%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,522 in reported general payments places this provider in the 60th percentile of 565 psychiatric/mental health providers in Missouri.

See all psychiatric/mental health providers in Missouri

Medicare billing

Part B allowed, 2024
$16,292
Medicare patients
73
Services billed
217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole21$34,450
LybalviOlanzapine/Samidorphan Malate11$17,153
Aripiprazole123$9,595
Duloxetine Hcl49$2,487
Haloperidol44$901
Quetiapine Fumarate55$739
Divalproex Sodium ErDivalproex Sodium42$492
Hydroxyzine Hcl35$471
Guanfacine Hcl32$452
Venlafaxine Hcl ErVenlafaxine Hcl46$446
Buspirone Hcl41$383
Olanzapine34$292
Lamotrigine41$248
Bupropion XlBupropion Hcl26$227
Divalproex Sodium63$226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$394$34,45021 claims
Alkermes, Inc.Lybalvi$16$17,15311 claims
Lilly USA, LLCOlanzapine$108$29234 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 565 psychiatric/mental health providers in Missouri.

Other psychiatric/mental health in Joplin

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →